Hospira has joined the Generic Pharmaceutical Association (GPhA). Hospira’s specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. Therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has pipelines of both generic and biosimilar drugs.

“Hospira is pleased to announce our membership in the GPhA,” said Thomas Moore, president, U.S., Hospira. “We commend the leadership shown by GPhA President Ralph Neas and the excellent staff he has assembled. GPhA is a strong industry trade association that will continue to work tirelessly to bring the safest, high-quality, lower-cost generic drugs to patients and families who need them, and Hospira looks forward to working with the association on the many pressing issues facing our industry.”

“We are pleased to welcome Hospira to GPhA, and we look forward to their joining in the Association’s mission to improve the lives of consumers by providing timely access to affordable pharmaceuticals,” said Ralph G. Neas, president and chief executive officer of GPhA. “Hospira’s products, like those of all our members, have enabled millions of Americans to obtain affordable treatments for critical conditions. Their input and participation will be a valuable asset for GPhA as we move into this new and exciting time for our industry.”